Trial Profile
THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms CANARIA
- 12 Apr 2017 Status changed from not yet recruiting to completed.
- 18 Feb 2015 New trial record